Strides Pharma hits all time high after USFDA approval for this drug

Strides Pharma share price today reached its all time high at Rs 1394.95 per share on the BSE, rising as much as 3.79 per cent in Friday's intraday deals

Pharma, medicine, Pharmaceuticals
SI Reporter New Delhi
2 min read Last Updated : Sep 06 2024 | 1:45 PM IST
Strides Pharma share price today reached its all time high at Rs 1394.95 per share on the BSE, rising as much as 3.79 per cent in Friday’s intraday deals. This came after the company announced that  its step-down wholly owned subsidiary Strides Pharma Global Pte. Limited in Singapore, has received approval for the generic version of Theophylline extended-release tablets, 300 mg and 450 mg, from the United States Food & Drug Administration (USFDA). 
The Theophylline tablets will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India, the company said in an exchange filing on Friday.
The product is a generic equivalent to the reference listed drug (RLD), Theo-Dur, of US based Schering Corp. Theophylline extended-release tablets are indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. 
The medication works as a bronchodilator, relaxing the muscles around the bronchial tubes to ease breathing. It is particularly helpful in preventing and treating symptoms such as wheezing, shortness of breath, and chest tightness. The extended-release formulation allows for prolonged drug release, reducing the frequency of dosing and providing consistent relief from symptoms over time.
Theophylline Extended-Release Tablets, 300 mg and 450 mg have a combined market size of $ 11.5 million, with the 300 mg dosage contributing $10.8 million, according to data by as per IQVIA. 
Headquartered in Bengaluru, India, Strides Pharma is an integrated manufacturer and exporter of finished pharmaceutical dosage forms for both branded and generic markets. It produces a broad range of ethical pharmaceuticals, over-the-counter (OTC) products, and nutraceuticals.
The company has a total market capitalisation of Rs 12,586.32 crore. Its shares are trading at a price to earnings multiple of 201.17 times with an earning per share of Rs 6.68 per share.
At 13:33 PM; the share price of the company was trading 1.84 per cent higher at Rs 2236.70. By comparison, the BSE Sensex was trading 0.13 per cent higher at 82,474 levels.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Buzzing stocksMarkets Sensex NiftyBSE NSEStrides Pharma

First Published: Sep 06 2024 | 1:45 PM IST

Next Story